Clinical effectiveness of four neuraminidase inhibitors (oseltamivir, zanamivir, laninamivir, and peramivir) for children with influenza A and B in the 2014-2015 to 2016-2017 influenza seasons in Japan

Nobuhisa Ishiguro; Naoko Koseki; Miki Kaiho; Tadashi Ariga; Hideaki Kikuta; Koji Oba; Takehiro Togashi; Keisuke Morita; Akira Inagawa; Akiko Okamura; Shigeru Yamazaki; Satoru Shida; Mutsuko Konno; Nobuaki Kawamura; Akihito Ishizaka; Kimihiko Takada; Keiji Tsubakihara; Naoko Nagano; Mutsuo Shibata; Hideto Furuyama; Yoshihiro Matsuzono; Akemi Koike; Mari Murashita; Yoshio Hatae; Hideki Arioka; Tatsuru Yamanaka; Toru Watanabe; Yuuichi Tabata; Yoshihiro Kumita; Kyosuke Hazama; Yasushi Akutsu; Hayato Aoyagi; Chie Tobise; Katsuki Azuma; Kohichi Yasoshima; Yoko Sawada; Kazuyuki Uetsuji; Akira Tsuchida; Akira Tsuchiyama; Kazue Yasuda; Yasuhisa Odagawa; Mikio Yoshioka

doi:10.1016/j.jiac.2018.01.013

Clinical effectiveness of four neuraminidase inhibitors (oseltamivir, zanamivir, laninamivir, and peramivir) for children with influenza A and B in the 2014-2015 to 2016-2017 influenza seasons in Japan

J Infect Chemother. 2018 Jun;24(6):449-457. doi: 10.1016/j.jiac.2018.01.013. Epub 2018 Feb 24.

Authors

Nobuhisa Ishiguro¹, Naoko Koseki², Miki Kaiho³, Tadashi Ariga³, Hideaki Kikuta⁴, Koji Oba⁵, Takehiro Togashi⁶, Keisuke Morita⁷, Akira Inagawa⁸, Akiko Okamura⁹, Shigeru Yamazaki¹⁰, Satoru Shida¹¹, Mutsuko Konno¹², Nobuaki Kawamura¹³, Akihito Ishizaka¹⁴, Kimihiko Takada¹⁵, Keiji Tsubakihara¹⁶, Naoko Nagano¹⁷, Mutsuo Shibata¹⁸, Hideto Furuyama¹⁹, Yoshihiro Matsuzono²⁰, Akemi Koike²¹, Mari Murashita²², Yoshio Hatae²³, Hideki Arioka²⁴, Tatsuru Yamanaka²⁵, Toru Watanabe²⁶, Yuuichi Tabata²⁷, Yoshihiro Kumita²⁸, Kyosuke Hazama²⁹, Yasushi Akutsu³⁰, Hayato Aoyagi³¹, Chie Tobise³², Katsuki Azuma³³, Kohichi Yasoshima³⁴, Yoko Sawada³⁵, Kazuyuki Uetsuji³⁶, Akira Tsuchida³⁷, Akira Tsuchiyama³⁸, Kazue Yasuda³⁹, Yasuhisa Odagawa⁴⁰, Mikio Yoshioka⁴¹

Affiliations

¹ Department of Pediatrics, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan. Electronic address: nishigur@med.hokudai.ac.jp.
² Department of Pediatrics, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan; Department of Pediatrics, Hokkaido Medical Center for Child Health and Rehabilitation, Sapporo, Japan.
³ Department of Pediatrics, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
⁴ Pediatric Clinic, Touei Hospital, Sapporo, Japan.
⁵ Department of Biostatistics, School of Public Health, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan; Interfaculty Initiative in Information Studies, The University of Tokyo, Tokyo, Japan.
⁶ Hokkaido Anti-Tuberculosis Association Sapporo Fukujuji Clinic, Sapporo, Japan.
⁷ Department of Pediatrics, Asahikawa Red Cross Hospital, Asahikawa, Japan.
⁸ Inagawa Pediatric Clinic, Muroran, Japan.
⁹ Umetsu Pediatric Clinic, Sapporo, Japan.
¹⁰ Ultra Pediatric Clinic, Ebetsu, Japan.
¹¹ Department of Pediatrics, Ebetsu City Hospital, Ebetsu, Japan.
¹² Department of Pediatrics, Sapporo-Kosei General Hospital, Sapporo, Japan.
¹³ Department of Pediatrics, Sapporo City General Hospital, Sapporo, Japan.
¹⁴ Sumiyoshi Pediatric Clinic, Chitose, Japan.
¹⁵ Takada Children's Clinic, Sapporo, Japan.
¹⁶ Tsubakibara Pediatric Clinic, Sapporo, Japan.
¹⁷ Nagano Pediatric Clinic, Asahikawa, Japan.
¹⁸ Department of Pediatrics, Health Sciences University of Hokkaido, Sapporo, Japan.
¹⁹ Department of Pediatrics, Japan Community Healthcare Organization Hokkaido Hospital, Sapporo, Japan.
²⁰ Matsuzono Pediatric Clinic, Sapporo, Japan.
²¹ Koike Children's Hospital, Sapporo, Japan.
²² Murashita Children's Clinic, Sapporo, Japan.
²³ Department of Pediatrics, Megumino Hospital, Eniwa, Japan.
²⁴ Mebae Pediatric Clinic, Sapporo, Japan.
²⁵ Yamanaka Tatsuru Pediatric Clinic, Sapporo, Japan.
²⁶ Watanabe Pediatric Allergy Clinic, Sapporo, Hokkaido, Japan.
²⁷ Iwamizawa Pediatric and Gynecology Clinic, Iwamizawa, Hokkaido, Japan.
²⁸ Kumita Pediatric Clinic, Chitose, Japan.
²⁹ Hazama Pediatric Clinic, Muroran, Japan.
³⁰ Akutsu Pediatric Clinic, Iwamizawa, Japan.
³¹ Department of Pediatrics, Obihiro Kyokai Hospital, Obihiro, Japan.
³² Tobise Pediatric Clinic, Asahikawa, Japan.
³³ Azuma Kodomo-Katei Clinic, Ebetsu, Japan.
³⁴ Makomanai Kids Clinic, Sapporo, Japan.
³⁵ Ikuai Pediatric Clinic, Sapporo, Japan.
³⁶ Nishioka Pediatric Clinic, Sapporo, Japan.
³⁷ Tsuchida Pediatric Clinic, Asahikawa, Japan.
³⁸ Shiroishi Pediatric Clinic, Sapporo, Japan.
³⁹ Department of Pediatrics, Sapporo Hokuyu Hospital, Sapporo, Japan.
⁴⁰ Department of Pediatrics, Otaru General Hospital, Otaru, Japan.
⁴¹ Department of Pediatrics, KKR Sapporo Medical Center, Sapporo, Japan.

PMID: 29487035
DOI: 10.1016/j.jiac.2018.01.013

Abstract

The clinical effectiveness of four neuraminidase inhibitors (NAIs) (oseltamivir, zanamivir, laninamivir, and peramivir) for children aged 0 months to 18 years with influenza A and B were investigated in the 2014-2015 to 2016-2017 influenza seasons in Japan. A total of 1207 patients (747 with influenza A and 460 with influenza B) were enrolled. The Cox proportional-hazards model using all of the patients showed that the duration of fever after administration of the first dose of the NAI was shorter in older patients (hazard ratio = 1.06 per 1 year of age, p < 0.001) and that the duration of fever after administration of the first dose of the NAI was shorter in patients with influenza A infection than in patients with influenza B infection (hazard ratio = 2.21, p < 0.001). A logistic regression model showed that the number of biphasic fever episodes was 2.99-times greater for influenza B-infected patients than for influenza A-infected patients (p < 0.001). The number of biphasic fever episodes in influenza A- or B-infected patients aged 0-4 years was 2.89-times greater than that in patients aged 10-18 years (p = 0.010), and the number of episodes in influenza A- or B-infected patients aged 5-9 years was 2.13-times greater than that in patients aged 10-18 years (p = 0.012).

Keywords: Influenza A; Influenza B; Laninamivir; Oseltamivir; Peramivir; Zanamivir.

MeSH terms

Acids, Carbocyclic
Adolescent
Betainfluenzavirus / drug effects
Betainfluenzavirus / genetics
Child
Child, Preschool
Cyclopentanes / administration & dosage*
Cyclopentanes / therapeutic use
Enzyme Inhibitors / administration & dosage*
Enzyme Inhibitors / therapeutic use
Female
Guanidines / administration & dosage*
Guanidines / therapeutic use
Humans
Infant
Infant, Newborn
Influenza A virus / drug effects
Influenza A virus / genetics
Influenza, Human / drug therapy*
Japan
Male
Neuraminidase / antagonists & inhibitors*
Oseltamivir / administration & dosage*
Oseltamivir / therapeutic use
Pyrans
Seasons
Sialic Acids
Treatment Outcome
Zanamivir / administration & dosage*
Zanamivir / analogs & derivatives*
Zanamivir / therapeutic use

Substances

Acids, Carbocyclic
Cyclopentanes
Enzyme Inhibitors
Guanidines
Pyrans
Sialic Acids
Oseltamivir
laninamivir
Neuraminidase
Zanamivir
peramivir